Serum vitamin B₁₂ and related 5-methyltetrahydrofolate-homocysteine methyltransferase reductase and cubilin genotypes predict neural outcomes across the Alzheimer's disease spectrum.

ABSTRACT: Epidemiological studies show mixed findings for serum vitamin B₁₂ (B₁₂) and both cognitive and regional volume outcomes. No studies to date have comprehensively examined, in non-supplemented individuals, serum B₁₂ level associations with neurodegeneration, hypometabolism and cognition across the Alzheimer's disease (AD) spectrum. Serum B₁₂ was assayed from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). Voxel-wise analyses regressed B₁₂ levels against regional grey matter (GM) volume and glucose metabolism (P < 0·05, family-wise corrected). For ADNI GM, there were thirty-nine cognitively normal (CN), seventy-three mild cognitive impairment

SUBMITTER: McLimans KE 

PROVIDER: S-EPMC7494526 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature